

Date: 14/08/2023

| | |
|--|---|
| BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai - 400 001 Script Code : 539872 | National Stock Exchange of India Limited 5 th Floor, Exchange Plaza, Bandra Kurla Complex Bandra (East) Mumbai-400051 Script Code : BAJAJHCARE |
|--|---|

Dear Sir/Madam,

Sub : Outcome of Board Meeting & submission of Unaudited Financial Results for the quarter ended June 30, 2023.

We hereby inform you that at the meeting of the Board of Directors of our Company held today i.e. 14th August, 2023 has considered and approved the following:

- The unaudited Financial Statements for the quarter ended June 30, 2023, as recommended by the Audit Committee; and

Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015, we enclose the following:

- (i) Unaudited Financial Results for the quarter ended June 30, 2023 along with limited review report;
- Appointment of M/s. Walker Chandiok & Co LLP, Chartered Accountants (ICAI Firm Regn No.001076N/N500013), as the Statutory Auditors of the Company for the period of 5 years.
- Resignation of M/s. Paresh Rakesh & Associates LLP, Chartered Accountant (FRN. 119728W), as an Internal Auditor of the Company.
- Appointment of M/s. V J Shah & Co, Chartered Accountant, as an Internal Auditor of the Company for the Financial Year 2023-24.

The requisite disclosure, pursuant to Para A of Schedule III of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015 read with Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13th July, 2023, is enclosed as Annexure 'A'.



The above information will also be available on the Company's website at www.bajajhealth.com. This is for your information and records.

We wish to inform you that Board Meeting commenced today at 4.00 p.m. and concluded at 6.20 p.m.

Kindly take the same on record.

Thanking you,

**For and on behalf of Board of Directors
of Bajaj Healthcare Limited**

**Anil Jain
Managing Director
DIN: 00226137**

BAJAJ HEALTHCARE LIMITED

Registered Office: 602-606, Bhoomi Velocity Infotech Park, Plot No: B-39, B-39A, B-39A/1, Road No. 23, Wagle Ind. Estate, Thane (West), Thane - 400604

Tel. : + 91 22 66177400/ 401; Fax : +91 22 66177458; E-mail : bajajhealth@bajajhealth.com

CIN No. L99999MH1993PLC072892

Annexure-A

**Disclosure pursuant to Para A of Part A of Schedule III of
Regulation 30 of the SEBI (Listing Obligations and Disclosure
Requirements) Regulation, 2015 read with Circular No.
SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13th July, 2023**

| Sr. No | Particulars | Disclosure | Disclosure | Disclosure |
|---------------|--|---|---|---|
| 1 | Reason of change viz appointment, resignation, removal, death or otherwise | Appointment of M/s. Walker Chandiok & Co LLP, Chartered Accountants(ICAI Firm Regn No. 001076N/N500013) Statutory Auditor for term of Five consecutive years i.e is from the conclusion of 30 th Annual General Meeting till 35 th Annual General Meeting | Resignation as Internal auditor of M/s. Paresh Rakesh & Associates LLP, Chartered Accountant Mumbai (Firm Regn No. 119728W/W110743) - As Management have decided to appoint new Internal Auditor to meet the evolving needs of the Company. | Appointment of Internal Auditor for FY 2023-24. |
| 2 | Date of Appointment & Term of appointment | Appointment approved in the Board meeting held on 14 th August, 2023, subject to the approval of Shareholders. | w.e.f 14 th August, 2023 | Appointed w.e.f 14 th August, 2023. For financial Year 2023-24. |
| 3 | Brief Profile | As per Schedule I | Not Applicable | V J Shah & Co, Chartered Accountants is a multi-disciplinary professional services organization rendering a range of value-added services to businesses of all sizes and sectors since 1982. It's a one-stop solution for various business and individual requirements. |

"Schedule I"

About Walker Chandiook & Co LLP

| | |
|------------------------------------|--|
| Date of establishment | 01 Jan 1935 |
| Date of conversion to LLP | 25 Mar 2014 |
| Registrations and empanelment | The Institute of Chartered Accountants of India Public Company Accounting Oversight Board Comptroller and Auditor General of India |
| Registered office | L-41, Connaught Circus, New Delhi-110001 |
| Number of partners* | 67 |
| Number of qualified staff* | 935+ |
| Number of trainees* | 525+ |
| Number of other employees* | 545+ |
| Total number of partners and staff | 2072+ |
| Number and Location of Offices* | 15 [Bengaluru, Chandigarh, Chennai, Delhi (2 offices including head office) Gurgaon, Hyderabad, Kolkata, Mumbai (2 offices), Noida, Pune, Kochi, Dehradun and Ahmedabad] |

*As at 01 May 2023

Independent Auditor's Review Report on Unaudited Quarterly Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Bajaj Healthcare Limited

1. We have reviewed the accompanying statement of unaudited financial results ('the Statement') of **Bajaj Healthcare Limited** ('the Company') for the quarter ended **30 June 2023** being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. The Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

Chartered Accountants

Offices in Bengaluru, Chandigarh, Chennai, Gurugram, Hyderabad, Kochi, Kolkata, Mumbai, New Delhi, Noida and Pune




Walker Chandiook & Co LLP is registered with limited liability with identification number AAC-2085 and its registered office at L-41 Connaught Circus, New Delhi, 110001, India

Walker ChandioK & Co LLP

5. The review of unaudited quarterly financial results for the period ended 30 June 2022 and audit of financial results for the quarter and year ended 31 March 2023 included in the Statement was carried out and reported by Chaturvedi & Agrawal (predecessor auditor) who had expressed unmodified conclusion vide their review report dated 12 August 2022 and unmodified audit opinion vide their audit report dated 30 May 2023, respectively, whose reports have been furnished to us and which have been relied upon by us for the purpose of our review of the Statement. Our conclusion is not modified in respect of this matter.

For **Walker ChandioK & Co LLP**
Chartered Accountants
Firm Registration No: 001076N/N500013



Ashish Gupta
Partner
Membership No. 504662



UDIN: 23504662BGWGGF5605

Place: New Delhi
Date: 14 August 2023

BAJAJ HEALTHCARE LIMITED
(CIN No. : L99999MH1993PLC072892)
UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED ON 30 JUNE 2023
(Rs. In Lakhs Except for Earnings Per Share)

| Particulars | Quarter Ended | | | Year Ended |
|---|-------------------|------------------|------------------|-------------------|
| | 30 June 2023 | 31 March 2023 | 30 June 2022 | 31 March 2023 |
| | (Unaudited) | (Audited) | (Unaudited) | (Audited) |
| A. Continuing Operations | | | | |
| I. Revenue from operations | 12,973.68 | 15,411.03 | 16,379.21 | 64,579.61 |
| II. Other Income | 21.81 | 72.04 | 66.91 | 158.98 |
| III. Total Income (I+II) | 12,995.49 | 15,483.07 | 16,446.12 | 64,738.59 |
| IV. Expenses | | | | |
| (a) Cost of materials consumed | 7,612.58 | 7,619.68 | 11,984.42 | 40,766.42 |
| (b) Changes in Inventories of Finished Goods and Work in Progress | (119.61) | 1,410.41 | (1,797.98) | (2,488.20) |
| (c) Employee benefits expense | 1,046.46 | 1,031.32 | 949.09 | 4,231.83 |
| (d) Finance Costs | 875.08 | 596.82 | 258.05 | 1,756.10 |
| (e) Depreciation and amortisation expense | 630.73 | 469.44 | 408.45 | 1,720.82 |
| (f) Other expenses | 2,259.78 | 3,147.34 | 2,796.99 | 10,933.41 |
| Total Expenses | 12,305.02 | 14,275.01 | 14,599.02 | 56,920.38 |
| V. Profit before Tax from Continuing Operations | 690.47 | 1,208.06 | 1,847.10 | 7,818.21 |
| VI. Tax Expense | | | | |
| (a) Current tax | - | 165.00 | 426.00 | 1,572.00 |
| (b) Earlier Years | - | 63.76 | - | 63.76 |
| (c) Deferred Tax Charge / (Credit) | (12.18) | (135.84) | (14.07) | (170.79) |
| Total Tax Expenses | (12.18) | 92.92 | 411.93 | 1,464.97 |
| VII. Profit after Tax from Continuing Operations | 702.65 | 1,115.14 | 1,435.17 | 6,353.24 |
| B. Discontinued Operations | | | | |
| VIII. Loss before Tax from Discontinued Operations | (5,686.47) | (707.84) | (231.52) | (1,996.57) |
| IX. Tax Expense / (Credit) of Discontinued Operations | (162.66) | 48.06 | 1.77 | 54.24 |
| X. Loss after Tax from Discontinued Operations | (5,523.81) | (755.90) | (233.29) | (2,050.81) |
| XI. Profit / (Loss) for the period / year (VII + X) | (4,821.16) | 359.24 | 1,201.88 | 4,302.43 |
| XII. Other comprehensive Income | | | | |
| Continuing Operations | | | | |
| (i) Items that will not be reclassified to profit or loss | - | 42.67 | - | 42.67 |
| (ii) Income tax relating to items that will not be reclassified to profit or loss | - | (10.74) | - | (10.74) |
| Total Other Comprehensive Income from Continuing Operations | - | 31.93 | - | 31.93 |
| Discontinued Operations | | | | |
| (i) Items that will not be reclassified to profit or loss | - | - | - | - |
| (ii) Income tax relating to items that will not be reclassified to profit or loss | - | - | - | - |
| Total Other Comprehensive Income from Discontinued Operations | - | - | - | - |
| XIII. Total Comprehensive Income for the Period / Year | (4,821.16) | 391.17 | 1,201.88 | 4,334.36 |
| XIV. Paid-up Equity Share Capital (Face Value Rs. 5/-) | 1,379.92 | 1,379.92 | 1,379.92 | 1,379.92 |
| XV. Other Equity | | | | 35,389.02 |
| XVI. EPS (Not Annualised for the Quarter) | | | | |
| Continuing Operations | | | | |
| (a) Basic & Diluted (in Rs.) | 2.55 | 4.04 | 5.20 | 23.02 |
| Discontinued Operations | | | | |
| (a) Basic & Diluted (in Rs.) | (20.02) | (2.74) | (0.85) | (7.43) |
| Total Operations | | | | |
| (a) Basic & Diluted (in Rs.) | (17.47) | 1.30 | 4.35 | 15.59 |



Note :

- a) The above financial results have been reviewed by the Audit Committee and subsequently approved by Board of Directors at their respective meetings held on 14 August 2023 and subjected to limited review carried out by Statutory Auditors who have expressed unmodified review conclusion.
- b) The above unaudited financial results for the quarter ended 30 June 2023 have been prepared in accordance with the Indian Accounting Standards (IND AS) notified under Section 133 of the Companies Act, 2013 (Act) read with relevant rules-Companies (Indian Accounting Standards) Rules, 2015 as amended, other accounting principles generally accepted in India and guidelines issued by Securities and Exchange Board of India.
- c) The Company deals in pharmaceuticals products (formulations and active pharmaceutical ingredients components) which are interlinked and interdependent. Therefore, the Company identified only one reportable segment i.e. Pharmaceuticals.
- d) The Board of Directors in their meeting held on 28 June 2023 approved to sale/disposal of undertaking/unit(s) on going concern basis, situated at plot no. N-92, L-9/3 , T-30, MIDC Tarapur, Taluka- Boisar, District Palghar, Maharashtra and vacant industrial land situated at plot no. D-2/CH/42 & D-2/CH/43 Dahej industrial area, GIDC, Bharuch, Gujarat (which were acquired under SARFAESI ACT, 2022 from Saraswat Bank) and plot no.E-62 and E-63 MIDC Tarapur, Taluka Boisar, District Palghar, Maharashtra. Approval of shareholders has been obtained vide postal ballot. The management has classified the assets and liabilities in relation to these units as Assets and liabilities held for sale/disposal under Ind AS 105 ("Non-current Assets Held for Sale and Discontinued Operations"). The results of the operation of these units have been presented separately on the statement of profit and loss as discontinued operations. Considering these assets are held for sale, the assets have been recorded at their fair value on the date these assets has been classified as held for sale.

The financial information from discontinued operations:

| Particulars | Quarter Ended | | | Year Ended |
|--|---------------|------------|-------------|------------|
| | 30.06.2023 | 31.03.2023 | 30.06.2022 | 31.03.2023 |
| | (Unaudited) | (Audited) | (Unaudited) | (Audited) |
| Total Income (A) | 690.21 | 433.78 | 827.76 | 2,750.37 |
| Total Expenses (B) | 6,376.68 | 1,141.62 | 1,059.28 | 4,746.94 |
| Loss before Tax from Discontinued Operations (C = A - B) | (5,686.47) | (707.84) | (231.52) | (1,996.57) |
| Tax Expense / (Credit) from Discontinued Operations (D) | (162.66) | 48.06 | 1.77 | 54.24 |
| Loss after Tax from Discontinued Operations (E = C - D) | (5,523.81) | (755.90) | (233.29) | (2,050.81) |

- e) The Figures for quarter ended 31 March 2023 are balancing figure between audited figures in respect of the full financial year and the published figures of the nine months ended 31 December 2022, which were subjected to limited review by the statutory auditors.

For and on Behalf of the Board
For Bajaj Healthcare Limited


Mr. Anil C. Jain
DIN : 00226137
Managing Director



Date : 14 August 2023
Place: Thane

